These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15065081)

  • 1. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
    Mitsch A; Böhm M; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
    Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by arylthienylacryloylaminobenzophenones.
    Mitsch A; Altenkämper M; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2005 Jan; 338(1):9-17. PubMed ID: 15674808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones.
    Mitsch A; Böhm M; Wissner P; Sattler I; Schlitzer M
    Bioorg Med Chem; 2002 Aug; 10(8):2657-62. PubMed ID: 12057654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
    Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
    Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors.
    Schlitzer M
    Curr Pharm Des; 2002; 8(19):1713-22. PubMed ID: 12171543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of aralkylsubstituted benzophenones.
    Mitsch A; Wissner P; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2001 Feb; 334(2):40-4. PubMed ID: 11268773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-thiol farnesyltransferase inhibitors: evaluation of different AA(X)-peptidomimetic substructures in combination with arylic cysteine replacements.
    Sakowski J; Böhm M; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2002 Apr; 335(4):135-42. PubMed ID: 12112033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of farnesyltransferase: 5-arylacryloylaminobenzophenones show antimalarial activity.
    Wiesner J; Ortmann R; Mitsch A; Wissner P; Sattler I; Jomaa H; Schlitzer M
    Pharmazie; 2003 Apr; 58(4):289-90. PubMed ID: 12749417
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Böhm M; Sattler I
    Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective farnesyl transferase inhibitors.
    Millet R; Domarkas J; Houssin R; Gilleron P; Goossens JF; Chavatte P; Logé C; Pommery N; Pommery J; Hénichart JP
    J Med Chem; 2004 Dec; 47(27):6812-20. PubMed ID: 15615530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of novel anti-malarial agents part 8. Effect of different central aryls in biarylacryloylaminobenzophenones on antimalarial activity.
    Wiesner J; Mitsch A; Altenkämper M; Ortmann R; Jomaa H; Schlitzer M
    Pharmazie; 2003 Dec; 58(12):854-6. PubMed ID: 14703959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity.
    Kettler K; Wiesner J; Silber K; Haebel P; Ortmann R; Sattler I; Dahse HM; Jomaa H; Klebe G; Schlitzer M
    Eur J Med Chem; 2005 Jan; 40(1):93-101. PubMed ID: 15642414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of novel aryl binding sites of farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors.
    Böhm M; Mitsch A; Wissner P; Sattler I; Schlitzer M
    J Med Chem; 2001 Sep; 44(19):3117-24. PubMed ID: 11543680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors.
    Sakowski J; Böhm M; Sattler I; Dahse HM; Schlitzer M
    J Med Chem; 2001 Aug; 44(18):2886-99. PubMed ID: 11520197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials.
    Kohring K; Wiesner J; Altenkämper M; Sakowski J; Silber K; Hillebrecht A; Haebel P; Dahse HM; Ortmann R; Jomaa H; Klebe G; Schlitzer M
    ChemMedChem; 2008 Aug; 3(8):1217-31. PubMed ID: 18470859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase.
    Wang GT; Wang X; Wang W; Hasvold LA; Sullivan G; Hutchins CW; O'Conner S; Gentiles R; Sowin T; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2005 Jan; 15(1):153-8. PubMed ID: 15582430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Sattler I
    Eur J Med Chem; 2000; 35(7-8):721-6. PubMed ID: 10960188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-peptidic, non-prenylic bisubstrate farnesyltransferase inhibitors. Part 3: structural requirements of the central moiety for farnesyltransferase inhibitory activity.
    Schlitzer M; Böhm M; Sattler I
    Bioorg Med Chem; 2000 Oct; 8(10):2399-406. PubMed ID: 11058034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.